Program Description

Supported By: Adaptimmune

Join us for an insightful discussion on an innovative treatment for certain patients with advanced synovial sarcoma. This program will delve into the critical role of biomarker profiling in identifying eligible candidates for T-cell therapy, underscoring its potential to transform outcomes in this challenging disease. Attendees will explore the scientific rationale behind TCR T-cell therapy and its application in targeting advanced synovial sarcoma, providing a deeper understanding of the mechanisms driving this innovative approach.

Additionally, we will examine key outcomes from the Phase 2 SPEARHEAD-1 trial showcasing the efficacy and safety profile of a novel T-cell therapy. The discussion will also include practical guidance on establishing solid tumor cell therapy treatment centers. Don’t miss this opportunity to gain actionable insights and engage with leading experts shaping the future of synovial sarcoma treatment.

Speakers

Allison Betof Warner, MD, PhD
Medical Oncology
Assistant Professor of Medicine
Stanford Cancer Center
Stanford, CA

Frederick Locke, MD
Blood and Marrow Transplant and Cellular Immunotherapy
Department Chair and Senior Member
Moffitt Cancer Center
Tampa, FL

---

Resources

Email / Contact Information: [email protected]

This promotional activity is provided by Adaptimmune and is not certified for continuing education credit. The content of Product & Innovation Theater and opinions expressed by presenters are those of the sponsor or presenters and not of the Tandem Meetings, ASTCT, or CIBMTR.